To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Definitive Healthcare (NasdaqGS:DH) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker2Welcome to Definitive Healthcare's Q3 2025 earnings call. Later, we will conduct a question-and-answer session. I will now like to turn the call over to your host. You may begin.Speaker1Good afternoon. Thank you for joining us today to review Definitive Healthcare's financial results. Joining me on the call today are Kevin Coop, Chief Executive Officer, and Casey Heller, CFO. During this call, we will make forwar ...

Third quarter 2025 earnings presentation November 6, 2025 Cautionary statement regarding forward-looking statements This presentation includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be iden ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Delaware 86-3988281 (State or other ...

Exhibit 99.1 Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025 Third Quarter Revenue Delivered at High End of Guidance Framingham, MA (November 6, 2025) – Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: "We delivered third quarter results at or above the high end of ...

Core Insights - Definitive Healthcare reported third quarter results that met or exceeded the high end of their guidance, with Adjusted EBITDA surpassing expectations by $2 million [3] - The company is focused on operational initiatives and investments to enhance performance over time, showing improvements in new customer acquisition and retention rates [3] Financial Highlights - Revenue for Q3 2025 was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024 [6] - Net loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, which included goodwill impairment charges of $228.2 million [6] - Adjusted Net Income was $9.7 million, down from $15.4 million in Q3 2024 [6] - Adjusted EBITDA was $18.9 million, or 32% of revenue, compared to $20.6 million, or 33% of revenue in Q3 2024 [6] Business and Operating Highlights - The company secured new customer wins across all end-markets, providing critical data and insights [4][7] - A large multi-national biopharma selected Definitive Healthcare to enhance their medical affairs operations, demonstrating the value of their Key Opinion Leader datasets [7] - A medical device company transitioned to Definitive Healthcare after their previous provider failed to deliver necessary insights, highlighting the company's competitive advantage [7] Guidance and Outlook - For Q4 2025, revenue is expected to be in the range of $59.0 – $60.0 million, with Adjusted Operating Income anticipated between $13.5 – $14.5 million [8] - Adjusted EBITDA is projected to be in the range of $16.0 – $17.0 million, with an adjusted EBITDA margin of 27 – 29% [8] - Full year 2025 revenue is expected to be between $239.0 – $240.0 million, raising the bottom end of the prior range by $2.0 million [15]

Core Insights - Definitive Healthcare Corp. will report its financial results for Q3 2025 on November 6, 2025, after market close [1] - A conference call and webcast will be held at 5:00 PM (ET) to discuss the financial results [1] Company Overview - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence [3] - The company provides SaaS products and solutions to help clients identify market opportunities and achieve commercial success in the healthcare sector [3]

Core Insights - Salubrum has launched a commercialization engine for healthcare growth, utilizing an AI-first approach to automate traditional marketing agency functions [1][6] - The company aims to redefine patient activation in healthcare by partnering with Definitive Healthcare to enhance market strategies for healthcare brands [1][7] Company Background - Founded by Osama Usmani, Salubrum initially focused on medical tourism but pivoted to address commercialization challenges in healthcare [3] - The company identified that healthcare providers were not inaccessible but rather invisible to patients, prompting the development of a new connection model [3] Patient Acquisition Strategy - Salubrum's AI engine addresses the difficulties healthcare providers face in acquiring patients online by filtering out low-quality search results and unsafe options [4] - The goal is to connect healthcare providers with high-intent patients, thereby building trust and improving access [4][5] Vertical Specialization - Salubrum emphasizes true vertical specialization, with its AI tailored to the unique rules, compliance, and KPIs of the healthcare sector [6] - The company aims to automate agency functions and disrupt legacy models through data-driven solutions [6][7] Market Positioning - Salubrum's vertical AI solution is designed to replace traditional agencies in the healthcare industry, supported by strategic partnerships and investments [7][10] - The company has achieved $60,000 in Annual Recurring Revenue (ARR) and a valuation of $2 million [7] Future Vision - Salubrum is focused on creating a new category of brand growth in healthcare marketing, enabling businesses to automate workflows and outperform traditional agencies [8] - The proprietary datasets used by Salubrum allow for true 1:1 programmatic advertising, making high-quality marketing accessible to small and medium enterprises (SMEs) [8][9] Company Support and Backing - Salubrum is backed by Forum Ventures and supported by NEXT Canada and Artest Management Group [10]

Core Viewpoint - Definitive Healthcare Corp. (DH) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook for its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that rising earnings estimates can lead to higher stock prices [4][6]. - Definitive Healthcare's earnings estimates have increased by 23.1% over the past three months, reflecting a positive trend in its business outlook [8]. Zacks Rating System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - The Zacks Rank 2 upgrade for Definitive Healthcare places it among the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].